Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
Healthcare
$95.74 +0.65%
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
52W Low $10.77High $91.00
Volume 0.52M
Average 1.55M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$88.21M
FY 2025 · Annual
Investing Cash Flow
-$96.75M
FY 2025 · Annual
Financing Cash Flow
$170.31M
FY 2025 · Annual
-62.1% YoYCash Flow Statement
USD
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.74M) | (19.32M) | (9.93M) | (83.72M) | (105.43M) |
| Depreciation & Amortization | 93K | 91K | 114K | 27K | 83K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.88M | (28K) | (1.66M) | 11.59M | (2.56M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.1M | (411K) | (783K) | 3.46M | 693K |
| Other Working Capital | 776K | 383K | (878K) | 8.13M | (3.25M) |
| Other Non-Cash Items | 43K | 497K | 561K | 14.27M | 19.7M |
| Operating Cash Flow | (7.73M) | (18.76M) | (10.91M) | (57.84M) | (88.21M) |
| Capital Expenditures | (19K) | (43K) | (2K) | (189K) | (209K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (329.94M) | (520.96M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 424.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (19K) | (43K) | (2K) | (330.13M) | (96.75M) |
| Debt Repayment | (408K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 48.86M | 23.09M | 0 | 449.54M | 170.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 48.45M | 23.09M | 0 | 449.54M | 170.32M |
| Effect of Forex Changes | 0 | 0 | 0 | (37.43M) | 0 |
| Net Change in Cash | 40.71M | 4.29M | (10.91M) | 24.14M | (14.64M) |
| Free Cash Flow | (7.74M) | (18.81M) | (10.91M) | (58.03M) | (88.42M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$105.4M
+ D&A$83.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$2.6M
+ Other Non-Cash$19.7M
= Operating Cash Flow-$88.2M
- Capex-$209.0K
= Free Cash Flow-$88.4M
Analysis
FY2025 free cash flow is -$88.4M. FCF conversion is 83.9% of net income. Operating cash flow was -$88.2M, with capex of -$209.0K. The largest bridge item is Other Non-Cash at $19.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 8-K | Current report | Oct 26, 2026 |
Does ORKA generate free cash flow?
Oruka Therapeutics, Inc. (ORKA) generated -$88.42M of free cash flow in fiscal 2025.
How much operating cash flow does ORKA produce?
Operating cash flow was -$88.21M, before capital expenditures of $209,000.00.
Continue the stock analysis
Jump to another research area for this company.